A value assessment of patient-level outcomes and productivity loss for intravenous and subcutaneous lecanemab for patients with early Alzheimer’s disease
SC treatments show value as a therapeutic option. IV and SC lecanemab availability may offer benefits to patients, caregivers, and society, and improve shared decision making.
Authors
- Kerigo Ndirangu (ORCID: https://orcid.org/0000-0001-5737-3156)
- R Ressa
- Julen Zabala Mancebo
- Emtiyaz Chowdhury
- Jack Ettinger
- Laura Graham
- Carolyn Bodnar
Institutions
- PAREXEL International (United Kingdom) (GB)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1080/13696998.2025.2609499
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00